一名耶和华见证会信徒患免疫介导的血栓性血小板减少性紫癜——联合体外免疫吸附、卡泊单抗、类固醇和利妥昔单抗的疗效
Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.
作者信息
Cardesa-Salzmann Teresa Marta, Stephan Bernhard, Simon Arne, Furtwängler Rhoikos, Schöndorf Dominik, Heine Sabine, Torfah Eyad, Lux Margaux, Meyer Sonja, Graf Norbert
机构信息
Department of Pediatric Hematology & Oncology Universitätsklinikum des Saarlandes Homburg Germany.
Department of Hemostaseology and Transfusion Medicine Universitätsklinikum des Saarlandes Homburg Germany.
出版信息
Clin Case Rep. 2022 May 20;10(5):e05902. doi: 10.1002/ccr3.5902. eCollection 2022 May.
We report the case of a Jehovah's Witness adolescent patient with immune-mediated thrombotic thrombocytopenic purpura after SARS-Cov2 infection successfully treated without therapeutic plasma exchange (TPE) using caplacizumab, corticosteroids, rituximab, and extracorporeal immunoadsorption (EIA). Further patients for whom TPE is not an option might benefit from this approach.
我们报告了一例感染新型冠状病毒2后发生免疫介导的血栓性血小板减少性紫癜的耶和华见证会青少年患者，该患者在未进行治疗性血浆置换（TPE）的情况下，使用卡泊单抗、皮质类固醇、利妥昔单抗和体外免疫吸附（EIA）成功治愈。对于无法选择TPE的其他患者，这种方法可能有益。
Zotero 插件